Clinical Trial Update: Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo [Phase 3]

View source ↗

Summary

Long-term safety follow-up results for Ebola vaccine candidates Ad26.ZEBOV and/or MVA-BN-Filo from a Phase 3 study have been posted after termination of the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease
• Hemorrhagic Fever Ebola

Drugs mentioned

• Ad26.ZEBOV
• MVA-BN-Filo

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Hemorrhagic Fever, Ebola | Phase 3 | Status: TERMINATED | Results posted: 2024-01-02